<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02776514</url>
  </required_header>
  <id_info>
    <org_study_id>W-560</org_study_id>
    <nct_id>NCT02776514</nct_id>
  </id_info>
  <brief_title>Steroids, Hyaluronic Acid or Platelet Rich Plasma Versus Placebo for the Knee Osteoarthritis</brief_title>
  <acronym>KIT</acronym>
  <official_title>Intraarticular Injections of Steroids, Hyaluronic Acid or Platelet Rich Plasma Versus Placebo for the Knee Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Balgrist University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stiftung f√ºr Rheumaforschung Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stiftung Marie-Lou Ringgenberg Bern</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Balgrist University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates clinical outcome and imaging outcome parameters after intraarticular
      injection of steroids, platelet-rich-plasma (prp), hyaluronic acid or placebo in patients
      with early osteoarthritis of the knee joint.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Osteoarthritis of the knee joint is a very common disease in middle aged and elderly
      patients. This study evaluates the efficiency of different commonly used substances for
      intraarticular, non-operative treatment in early stages of this disease.

      240 patients receive an fluoroscopic guided injection in the knee joint: 60 patients get
      injection with steroids 60 patients get injection with prp 60 patients get injection with
      hyaluronic acid 60 patients get injection with placebo (iopamiro contrast media)

      Primary outcome: - clinical outcome (pain using numeric rating scale)

        -  Magnetic Resonance imaging (cartilage defects etc.)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>up to 18 months after injection</time_frame>
    <description>numeric rating scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnetic Resonance imaging</measure>
    <time_frame>up to 12 months after injection</time_frame>
    <description>cartilage volume (ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnetic Resonance imaging</measure>
    <time_frame>up to 12 months after injection</time_frame>
    <description>T2-values in cartilage (mean Signal +/- Standard Deviation) in subregions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC score</measure>
    <time_frame>up to 18 months after injection</time_frame>
    <description>Clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tegner Score</measure>
    <time_frame>up to 18 months after injection</time_frame>
    <description>Clinical outcome</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Triamcort (1 ml, 40 mg/ml)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 patients receive intraarticular injection with steroids (and contrast media Iopamiro 200)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Platelet-rich-plasma (PRP 3 ml)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 patients receive intraarticular injection with platelet-rich-plasma (PRP) (and contrast media Iopamiro 200)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Suplasyn1-shot (60 mg/ ml)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>60 patients receive intraarticular injection with hyaluronic acid (and contrast media Iopamiro 200)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Iopamiro 200)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>60 patients receive intraarticular injection with contrast media only</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcort</intervention_name>
    <description>Fluoroscopic guided injection in the knee joint</description>
    <arm_group_label>Triamcort (1 ml, 40 mg/ml)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platelet-rich-plasma</intervention_name>
    <arm_group_label>Platelet-rich-plasma (PRP 3 ml)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suplasyn1</intervention_name>
    <arm_group_label>Suplasyn1-shot (60 mg/ ml)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo (Iopamiro 200)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gonarthritis Kellgren 1,2 with symptoms

          -  german speaking

          -  informed consent

        Exclusion Criteria:

        -age under 18, gonarthritis Kellgren 3 and 4, anticoagulation therapy, known inflammatory
        disease or infection, cardiovascular disease NYHA IV, immunosuppression, contraindication
        for MRI, pregnancy, no informed consent, NSAR 3 days before injection, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea B Rosskopf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiology University Hospital Balgrist</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea B Rosskopf, MD</last_name>
    <phone>141 44 386 33 11</phone>
    <email>andrea.rosskopf@balgrist.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcel Tschopp, MD</last_name>
    <phone>141 44 386 5208</phone>
    <email>marcel.tschopp@balgrist.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Balgrist</name>
      <address>
        <city>Zurich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea B Rosskopf, MD</last_name>
      <phone>+41 44 386 3311</phone>
      <email>andrea.rosskopf@balgrist.ch</email>
    </contact>
    <contact_backup>
      <last_name>Marcel Tschopp, MD</last_name>
      <phone>+41 44 386 5208</phone>
      <email>marcel.tschopp@balgrist.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Christian WA Pfirrmann, MD, MBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 18, 2016</study_first_posted>
  <last_update_submitted>October 19, 2017</last_update_submitted>
  <last_update_submitted_qc>October 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

